Fig. 9: In vivo antitumor immune response.

a Representative immunofluorescent images of tumor sections to detect the CRT and HMGB1 levels (scale bar = 50 μm). b–d Percentages of CD80⁺ CD86⁺ DCs, CD8⁺ T cells, and CD4⁺ T cells in LNs. Quantification data of CD8⁺ T cells (e), central memory T cells (Tcm, CD44⁺CD62L⁺) (f), and effector memory T cells (Tem, CD44⁺CD62L⁻) (g) in spleens. Abundances of IFN-γ⁺ CD8⁺ T cells (h), CD4⁺ T cells (i), and T_reg cells (j) in tumors. k Percentages of PD-L1⁺ cells in tumors after different treatments. Flow cytometry analyses of M1 (l) and M2 (m) cells in tumors. Flow cytometry measurements of CD8⁺ T cells (n) and CD4⁺ T cells (o) in the DLNs of mice bearing with primary and brain metastatic tumors. Percentages of M1 (p) and M2 (q) cells in the brains after different treatments. r Representative immunofluorescent images of the brain to observe CD86⁺ and CD206⁺ cells (scale bar = 1 mm). Green and red fluorescence signals indicate CD86 and CD206, respectively. n = 4 mice per group for all the studies. All data are presented as mean ± SD. Two-tailed Student’s t test and One-way analysis of variance (ANOVA) with a Tukey post hoc test were used for the statistical comparison between the two groups and among multiple groups, respectively. A significant difference was considered when the p value was < 0.05. Source data are provided as a Source Data file.